Colleen Pearson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Colleen Pearson has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Guoying Wang
Department of Critical Care Medicine, The Second People’s Hospital of Dongying, China
5 shared publications - Xiaobin Wang
Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health Johns Hopkins University Bloomberg School of Public Health Baltimore Maryland USA
5 shared publications - Xiumei Hong
Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health Johns Hopkins University Bloomberg School of Public Health Baltimore Maryland USA
4 shared publications - Avi Z. Rosenberg
Department of Pathology, Johns Hopkins University School of Medicine
2 shared publications Cheryl A. Winkler
Cancer Innovation Laboratory, Center for Cancer Research National Cancer Institute and Basic Research Program, Frederick National Laboratory Frederick MD USA
2 shared publications- Jeffrey Burnett Kopp
National Institute of Diabetes and Digestive and Kidney Diseases
2 shared publications
Latest Publications
- 10 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (7) , 943-954
A Prospective Birth Cohort Study on the Association Between Cord Blood Acylcarnitine Profile and Childhood Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
- 10 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (7) , 943-954
A Prospective Birth Cohort Study on the Association Between Cord Blood Acylcarnitine Profile and Childhood Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
- Open Access
- 5 October 2025
- Published by Elsevier in Environment International
- Vol. 204, 109842
Changes in the levels and predictors of per- and poly-fluoroalkyl substances in maternal plasma, relative to timelines of EPA PFOA Stewardship
- 5 October 2025
- Published by Elsevier in Environment International
- Vol. 204, 109842
Open AccessChanges in the levels and predictors of per- and poly-fluoroalkyl substances in maternal plasma, relative to timelines of EPA PFOA Stewardship
- Open Access
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e039949
Prenatal Per‐ and Polyfluoroalkyl Substance Exposures and Longitudinal Blood Pressure Measurements in Children Aged 3 to 18 Years: Findings From a Racially and Ethnically Diverse US Birth Cohort
Background: Prenatal per‐ and polyfluoroalkyl substance (PFAS) exposures may influence offspring blood pressure (BP), but long‐term studies in diverse populations remain limited. Methods: Participants were from the Boston Birth Cohort. We measured PFAS in maternal plasma collected 24 to 72 hours after delivery and extracted children's BP from medical records. We calculated age‐, sex‐, and height‐specific BP percentiles and defined elevated BP as systolic/diastolic BP ≥90th percentile (ages 3 to 3–5y =0.40; β 6–12y =1.06; β 13–18y =2.55), male (β male =1.51; β female =0.52), and Black (β Black =1.75; β Hispanic =0.45) children. In male children, each doubling of perfluoroheptanesulfonic acid (PFHpS) was associated with a 9% higher risk of elevated BP at ages 6 to 12 years and a 17% higher risk at 13 to 18 years, with no increased risk at 3 to 5 years. PFHpS was associated with a dose‐dependent divergence in BP trajectories beginning at age 13 years. Conclusions: Prenatal exposures to certain PFAS were associated with offspring BP, with stronger associations in adolescents, male children, and Black children. Prenatal PFAS exposures may have intergenerational, long‐term, and latent hypertensive effects.
- 17 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (12) , e039949
Open AccessPrenatal Per‐ and Polyfluoroalkyl Substance Exposures and Longitudinal Blood Pressure Measurements in Children Aged 3 to 18 Years: Findings From a Racially and Ethnically Diverse US Birth Cohort
Background: Prenatal per‐ and polyfluoroalkyl substance (PFAS) exposures may influence offspring blood pressure (BP), but long‐term studies in diverse populations remain limited. Methods: Participants were from the Boston Birth Cohort. We measured PFAS in maternal plasma collected 24 to 72 hours after delivery and extracted children's BP from medical records. We calculated age‐, sex‐, and height‐specific BP percentiles and defined elevated BP as systolic/diastolic BP ≥90th percentile (ages 3 to 3–5y =0.40; β 6–12y =1.06; β 13–18y =2.55), male (β male =1.51; β female =0.52), and Black (β Black =1.75; β Hispanic =0.45) children. In male children, each doubling of perfluoroheptanesulfonic acid (PFHpS) was associated with a 9% higher risk of elevated BP at ages 6 to 12 years and a 17% higher risk at 13 to 18 years, with no increased risk at 3 to 5 years. PFHpS was associated with a dose‐dependent divergence in BP trajectories beginning at age 13 years. Conclusions: Prenatal exposures to certain PFAS were associated with offspring BP, with stronger associations in adolescents, male children, and Black children. Prenatal PFAS exposures may have intergenerational, long‐term, and latent hypertensive effects.
- Open Access
- 21 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (22) , e029311
Joint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities: A US Racially and Ethnically Diverse Prospective Birth Cohort Study
Background: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods and Results: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow‐up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time‐to‐CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow‐up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between creatinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally underrepresented multiracial and multiethnic high‐risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03228875.
- 21 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (22) , e029311
Open AccessJoint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities: A US Racially and Ethnically Diverse Prospective Birth Cohort Study
Background: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods and Results: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow‐up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time‐to‐CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow‐up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between creatinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally underrepresented multiracial and multiethnic high‐risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03228875.
- 1 May 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (5) , 1092-1101
Cord Blood Insulin Concentration and Hypertension Among Children and Adolescents Enrolled in a US Racially Diverse Birth Cohort
Background: Although insulin resistance is closely related to hypertension, the debate continues as to whether insulin resistance is a cause or a consequence of hypertension. This study investigated the associations of cord blood insulin concentration with blood pressure (BP) and hypertension in childhood and adolescence. Methods: This study included 951 children enrolled from 1998 to 2012 and followed from birth onwards at the Boston Medical Center, Boston, MA. Cord blood insulin concentration was measured using a sandwich immunoassay. Hypertension in childhood and adolescence was defined based on the 2017 American Academy of Pediatrics Clinical Practice Guidelines. Results: The median (interquartile range) for cord blood insulin concentration was 12.1 (7.2–19.0) µIU/mL. The age range of BP measurements was 3 to 18 years (median, 10.6 years). Cord blood insulin concentration was positively associated with systolic and diastolic BP as well as the risk of hypertension at age 3 to 18 years. Compared with the lowest tertile of cord blood insulin concentration, the top tertile insulin concentration was associated with a 5.18 (95% CI, 1.97–8.39) percentile increase in systolic BP, 4.29 (95% CI, 1.74–6.84) percentile increase in diastolic BP, and 1.62-fold (95% CI, 1.27–2.08) higher risk of hypertension. The association between insulin and hypertension was stronger among children born preterm ( P for interaction=0.048). Furthermore, preterm birth and childhood overweight or obesity enhanced the associations. Conclusions: Our results suggest that elevated insulin concentration at birth plays a critical role in the early life origins of hypertension and support the hypothesis implicating insulin resistance in the etiology of hypertension.
- 1 May 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (5) , 1092-1101
Cord Blood Insulin Concentration and Hypertension Among Children and Adolescents Enrolled in a US Racially Diverse Birth Cohort
Background: Although insulin resistance is closely related to hypertension, the debate continues as to whether insulin resistance is a cause or a consequence of hypertension. This study investigated the associations of cord blood insulin concentration with blood pressure (BP) and hypertension in childhood and adolescence. Methods: This study included 951 children enrolled from 1998 to 2012 and followed from birth onwards at the Boston Medical Center, Boston, MA. Cord blood insulin concentration was measured using a sandwich immunoassay. Hypertension in childhood and adolescence was defined based on the 2017 American Academy of Pediatrics Clinical Practice Guidelines. Results: The median (interquartile range) for cord blood insulin concentration was 12.1 (7.2–19.0) µIU/mL. The age range of BP measurements was 3 to 18 years (median, 10.6 years). Cord blood insulin concentration was positively associated with systolic and diastolic BP as well as the risk of hypertension at age 3 to 18 years. Compared with the lowest tertile of cord blood insulin concentration, the top tertile insulin concentration was associated with a 5.18 (95% CI, 1.97–8.39) percentile increase in systolic BP, 4.29 (95% CI, 1.74–6.84) percentile increase in diastolic BP, and 1.62-fold (95% CI, 1.27–2.08) higher risk of hypertension. The association between insulin and hypertension was stronger among children born preterm ( P for interaction=0.048). Furthermore, preterm birth and childhood overweight or obesity enhanced the associations. Conclusions: Our results suggest that elevated insulin concentration at birth plays a critical role in the early life origins of hypertension and support the hypothesis implicating insulin resistance in the etiology of hypertension.
- Open Access
Joint associations of pregnancy complications and postpartum maternal renal biomarkers with severe cardiovascular morbidities: A US racially diverse prospective birth cohort study
Rationale & Objective: Pregnancy complications are risk factors for cardiovascular diseases (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods: This study included 576 mothers of diverse ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and cystatin C were measured 1-3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. Results: During an average of 10.3±3.2 years of follow-up, 34 mothers developed one or more CVD events. Although no significant associations were found between creatinine and risk of CVD, per unit increase of cystatin C (CysC) was associated with a hazard ratio (HR) of 5.21 (95%CI = 1.49-18.2) for CVD. A borderline significant interactive effect was observed between elevated CysC (≥75th percentile) and preeclampsia. Compared to those without preeclampsia and with normal CysC level (th percentile), mothers with preeclampsia and elevated CysC had the highest risk of CVD (HR=3.8, 95%CI = 1.4-10.2), while mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally under-represented multi-ethnic high-risk mothers, elevated maternal plasma cystatin C and pregnancy complications synergistically increased risk of CVD later in life. These findings warrant further investigation. Clinical Perspectives: What is new? Maternal postpartum elevated levels of cystatin C are independently associated with higher risk of cardiovascular diseases (CVD) later in life. Maternal pregnancy complications coupled with postpartum elevated levels of cystatin C synergistically increased future risk of CVD. What are the clinical implications? These findings, if further confirmed, suggest that women with pregnancy complications and elevated postpartum cystatin C may be at particular high risk for CVD later in life compared to women without these risk factors.
Open AccessJoint associations of pregnancy complications and postpartum maternal renal biomarkers with severe cardiovascular morbidities: A US racially diverse prospective birth cohort study
Rationale & Objective: Pregnancy complications are risk factors for cardiovascular diseases (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods: This study included 576 mothers of diverse ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and cystatin C were measured 1-3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. Results: During an average of 10.3±3.2 years of follow-up, 34 mothers developed one or more CVD events. Although no significant associations were found between creatinine and risk of CVD, per unit increase of cystatin C (CysC) was associated with a hazard ratio (HR) of 5.21 (95%CI = 1.49-18.2) for CVD. A borderline significant interactive effect was observed between elevated CysC (≥75th percentile) and preeclampsia. Compared to those without preeclampsia and with normal CysC level (th percentile), mothers with preeclampsia and elevated CysC had the highest risk of CVD (HR=3.8, 95%CI = 1.4-10.2), while mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally under-represented multi-ethnic high-risk mothers, elevated maternal plasma cystatin C and pregnancy complications synergistically increased risk of CVD later in life. These findings warrant further investigation. Clinical Perspectives: What is new? Maternal postpartum elevated levels of cystatin C are independently associated with higher risk of cardiovascular diseases (CVD) later in life. Maternal pregnancy complications coupled with postpartum elevated levels of cystatin C synergistically increased future risk of CVD. What are the clinical implications? These findings, if further confirmed, suggest that women with pregnancy complications and elevated postpartum cystatin C may be at particular high risk for CVD later in life compared to women without these risk factors.